Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | TYR | P14679 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.37 |
| ▸ | GBA1 | P04062 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10435880 | 0.87 | SLC6A2 (0.39) | SLC6A4SLC6A2HPGDSLC6A3 | |
| SCHEMBL18253219 | 0.83 | DHODH (0.42) | LMNATYRSLC6A4TSHRALDH1A1 | |
| SCHEMBL26424742 | 0.80 | DHODH (0.47) | LMNATYRSLC6A4TSHRALDH1A1 | |
| SCHEMBL23962417 | 0.79 | SLC6A4 (0.43) | TYRSLC6A4GBA1ALDH1A1SLC6A2 | |
| SCHEMBL26424750 | 0.77 | HSD11B1 (0.41) | LMNATYRSLC6A4TSHRALDH1A1 | |
| SCHEMBL23962816 | 0.75 | DHODH (0.43) | SLC6A4GBA1TSHRALDH1A1HSD17B10 | |
| Hydrochloric Acid SCHEMBL15794270 | 0.73 | GBA1 (0.56) | SLC6A4GBA1TSHRSLC6A2SLC6A3 | |
| SCHEMBL1956594 | 0.73 | LMNA (0.39) | LMNATYRSLC6A4TSHRALDH1A1 | |
| SCHEMBL26424747 | 0.72 | HTR2A (0.43) | LMNASLC6A4TSHRSLC6A2HPGD | |
| Tert-Butyl Formate SCHEMBL27596961 | 0.71 | SLC6A4 (0.48) | SLC6A4SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230130909-A1 | HPK1 INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230130909-A1 | HPK1 INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | WEE2, WEE1, HK1 | LMNA 2098/4885TYR 4157/4885SLC6A4 2912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.